Naltrexone injectable sustained release formulation
US12201630B2 · kind B2 · utility
0Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 26, 2019 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Mar 30, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0024
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an injectable sustained release pharmaceutical formulation, including 3-acyl-naltrexone or a pharmaceutically acceptable salt thereof, a biocompatible organic solvent, and optionally a biocompatible polymeric material. Also provided is a method for treating opioid use disorder or alcoholism, including administering the injectable sustained release pharmaceutical formulation to a subject in need thereof. The pharmaceutical formulation provides a sustained release profile after one single injection, and the plasma levels of naltrexone in minipigs could provide a sustained release for 2 months.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.